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Abstract
Background: Transcatheter aortic-valve implantation (TAVI) is a new therapeutic choice for treating aortic stenosis
in patients considered high risk for surgery. This blooming therapeutic technique still requires evaluation of
medium and long term outcome.
Method: We hereby report our results of the first 150 consecutive patients to receive TAVI implants in our
population recruited from July 2009 to March 2013 in a retrospective and monocentric study. We analyzed long
term morbidity and mortality criteria. We compared the apical and femoral approach results and researched
predictors of cardiac mortality.
Results: The mean monitoring period was 387.62 days, mean Euroscore was 21.8, and mean Society of Thoracic
Surgeons (STS) risk score was 9.2. The success rate for the procedure was 94.6 %. A total of 39 patients died. The
mortality rates at the immediate perioperative point, 30 days, 1 year, and 2 years, were 4 %, 11.3 %, 22.7 %, and 26
%, respectively. As regards complications, there were 10 hemodynamic complications (6.6 %) and 20 vascular
(13.3 %), 11 cardiac tamponades (7.4 %), eight mechanical (5.3 %), ten major hemorrhagic (6.7 %), 14 pulmonary
(9.3 %), and 18 infectious complications (12 %). When comparing the rates of reported complications in terms of
different approaches, we observed significantly more hemodynamic complications in the apical group (p = 0.049).
Pulmonary complications were also significantly more common in cases of apical approach (p = 0.029). The majority
of the patients reported clear functional improvement throughout their follow-up.
Conclusion: The results of the first 150 patients to receive the implant at the Nancy University Teaching Hospital
(CHU Nancy) were consistent with findings in the literature. TAVI proved a credible and effective alternative to
surgical valve replacement for patients at high risk during surgery.
Keywords: TAVI: Transcatheter aortic-valve implantation, Aortic stenosis, VARC: Valve Academic Research
Consortium
Background
Calcified aortic stenosis is the most common type of
valvular heart disease found among adults in Western
industrialized countries [1]. The etiology for this disease
is mainly degenerative, therefore those affected are pri-
marily of an advanced age. Observational studies dem-
onstrate that its prevalence increases significantly with
age, from 1.5 % for the 64–74-year age group to 4.8 %
for those aged 75 and over [1]. Since the first
percutaneous transcatheter implantation of an aortic
valve prosthesis [2], transcatheter aortic-valve implant-
ation (TAVI) has become a valid alternative to surgical
aortic valve replacement [3–6]. Our study analyzed the
first 150 patients treated with TAVI at the university
hospital of Nancy (CHU Nancy) and compared the re-
sults according to approach method. We were particu-
larly focused on studying and analyzing the mortality
rates at 31 days, 1 year, and 2 years, along with the
demographic features of the patient population, proced-
ural information, complications, clinical follow-up, and
echocardiography results.
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Methods
This study reports on the first 150 patients treated with
TAVI at CHU Nancy from July 2009 to March 2013.
This was a retrospective and monocentric study, yet
does include prospective data gathered for the France 2
[5] and France TAVI registries.
Patients indicated for TAVI procedures were selected
according to the guidelines of the Haute Autorité de
Santé (HAS), the French national health authority, after
the possibility of surgery was ruled out. Patient assess-
ment was carried out at a multidisciplinary meeting, tak-
ing into account surgical risk scores (logistic Euroscore
>20 % or Society of Thoracic Surgeons [STS] >10 %)
and comorbidities. Each patient treated was fully in-
formed and signed an informed consent form. The fol-
lowing information was collected before the procedure:
demographic information, blood parameter values, and
echocardiogram data. These same parameters were ana-
lyzed following surgery. The results were compared ac-
cording to the type of approach used and the implantation
success rate.
The effectiveness criteria consisted of the reduction in
mean transaortic gradient and increase in aortic surface.
The mortality rates were analyzed at several points: im-
mediately perioperatively, at 30 days, 6 months, 1 year,
2 years, and 3 years. We also researched the predictive
factors for cardiovascular mortality. Clinical follow-up,
consisting of functional status according to the New
York Heart Association [NYHA] classification, and
echocardiography were carried out at the follow-up
visits. Patient follow-up was performed at 6 months for
all patients then at 1, 2, and even 3 years for the most
elderly. This study involving the first 150 subjects thus
extended over a period of 3 years and 7 months. We
categorized the major complications in accordance with
the Valve Academic Research Consortium (VARC) clas-
sification [7].
Statistical analysis
The statistical analysis was carried out using the SPSS
17.0 software for Windows (Chicago, Illinois). Quantita-
tive variables were compared using paired and non-
paired t-tests or by analysis of variance (ANOVA).
Qualitative variables were compared using chi-squared
tests or Fisher’s exact test. We investigated the entire pa-
tient population for predictive event survival factors by
means of univariate Cox regression model. In order to
determine if these were the result of independent pre-
dictive factors, for each test a value of p < 0.05 was con-
sidered significant and for each significant variable we
stated the relative risk and 95 % confidence interval (CI).
The survival curves were determined using the Kaplan-
Meier method.
Results
The follow-up period extended from July 28th 2009 to
July 3rd 2013, making a total follow-up period of 3 years
and 9 months. In total, 150 patients were treated. The
mean monitoring period was 387.62 days, with a median
of 303.50 days (interquartile range [IQR]: 141.25-597.50).
The general features of the patient population have
been presented in Table 1. Mean age at implantation
was 82.6 years old. The mean Euroscore was 21.8 and
mean STS was 9.2. All patients manifested symptoms. A
study of the patient functional status revealed the follow-
ing: 66 % exhibited Class III dyspnoea (NYHA); there was
a high rate of coronary heart disease (46.7 %); both the
femoral and apical approach groups were homogeneous.
The primary differences were the following: there were
more patients with a history of heart and coronary by-
pass surgery in the apical group (p = 0.096 and p = 0.056,
respectively); there were significantly more smokers and
cases of chronic obstructive pulmonary disease (COPD)
in the apical group (p = 0.014 and p = 0.046, respect-
ively). In addition, with regard to symptomatology, there
were significantly more patients presenting with acute
pulmonary edema and cardiac decompensation in the
apical group (p = 0.02 and p = 0.049, respectively).
The echographic features are presented in Table 2, the
mean gradient and aortic orifice area were 52.8 mmHg
and 0.6 cm2. Mean left ventricular ejection fraction
(LVEF) was 52.8 %, 49.3 % of patients exhibited associ-
ated aortic insufficiency, 42 % had associated mitral re-
gurgitation, and the mean systolic arterial pressure was
46.3 mmHg.
Perioperative results
A total of 78 patients were treated using the femoral
route and 72 by the apical route. All operations were
carried out under general anesthetic. Only 149 pros-
theses were implanted, as one patient died when anes-
thetized. Of all the prostheses, 137 were Edwards Sapien
and 12 were CoreValve. The mean prosthesis diameter
was 25.6 mm. The success rate for the procedure was
94.6 %, taking into account the six patients who died im-
mediately during the operation and two failed proce-
dures. The different reasons for death in the operating
theatre were: one massive post-dilation aortic insuffi-
ciency, one cardiac arrest under anaesthetic, two rup-
tures of the aortic root after insertion of the prosthesis,
and two cases of cardiac tamponade with refractory state
of shock. The two failed procedure were one incorrect
position of the valve because of undersizing of the pros-
thesis resulting in the migration of the valve into the left
ventricle, treated by surgical conversion and aortic re-
placement, and one cardiac tamponade after insertion of
the catheter via the apical approach. The mean length of
hospital stay was 12.8 days +/− 10.7 days. Comparing
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the two approach routes, the apical group presented a sig-
nificantly longer mean hospital stay length, at 15.5 days
+/− 12.8 versus 10.3 days +/− 7.6 for the femoral group
(p = 0.002).
Mortality rates
In total, 39 patients died. Our study found that six died
in the operating theatre (4 %), 11 later within 31 days
(11.3 %), 14 within six months (21.3 %), two at one year
(22.7 %), and a further six had died by the 2-year point
(26 %). There were no further deaths after 2 years of fol-
low up and the mortality rate at both three and nine
months was therefore 26 %. By the 2-year follow-up, 25
patients had died from cardiovascular causes (16.7 %)
and 14 patients from non-cardiovascular causes (9.3 %).
The different causes of mortality were: dislocation of the
shoulder followed by confinement to bed, hepatocellular
cancer, septic shock passing a kidney stone, colon can-
cer, two cases of postoperative failure to thrive syn-
drome, kidney failure after 5 months, hepatocellular
failure with cirrhosis, confinement to the postoperative
cerebrovascular accident (CVA) suite, rectorrhagia, cere-
bral lymphoma, and three unexplained causes at one
year. Note that one patient died suddenly at home six
months after discharge from the hospital, the diagnosis
of sudden death was made; the patient did not have a
pacemaker (Figs. 1 and 2).
In our study, the probability of overall survival was
higher for the femoral approach group than the apical
group by a significant degree (p = 0.043). On comparing
cardiovascular mortality according to the route of ap-
proach, the rates were 10 % vs. 21 % for the femoral and
apical routes, respectively, at 6 months, 10 % vs. 21 % at
1 year, and 19 % vs. 25 % at 2 years. We found a non-
significant trend towards an increased probability of sur-
vival in the femoral group compared to the apical group
(p = 0.055).
Predictive factors of mortality
We found few predictive factors of cardiovascular mor-
tality. In particular, the Euroscore and STS surgical risk
assessment scores were not found to be significant. By
Table 1 Patient characteristics at baseline
Characteristics All patients (n = 150) Transfemoral approach (n = 78) Transapical approach (n = 72) p
Male gender 68 (45.3 %) 35 (44.9 %) 33 (45.8 %) NS
Age (years) 82.6 +/− 6.9 83.5 +/− 6.7 81.7 +/− 7.0 NS
BMI 25.4 +/− 4.1 24.9 +/− 4,2 24.9 +/− 4.1 NS
Coronary artery disease 70 (46.6 %) 32 (41.0 %) 38 (52.8 %) NS
PCI 43 (28.7 %) 21 (27.0 %) 22 (30.6 %) NS
Previous myocardial infarction 16 (10.7 %) 7 (9.0 %) 9 (12.5 %) NS
Previous cardiac surgery 31 (20.7 %) 12 (15.4 %) 19 (26.4 %) 0.096
CABG 28 (18.7 %) 10 (12.8 %) 18 (25.0 %) 0.056
Mitral mechanical prosthesis 1 (0.7 %) 0 (0 %) 1 (1.4 %) NS
Aortic bioprosthesis 2 (1.3 %) 2 (2.6 %) 0 (0 %) NS
Aortic balloon valvuloplasty 3 (2 %) 1 (1.3 %) 2 (2.8 %) NS
Hypertension 89 (59.3 %) 47 (60.3 %) 42 (58.4 %) NS
Diabetes 42 (28 %) 24 (30.8 %) 18 (25.0 %) NS
Smoking 46 (30.6 %) 17 (21.8 %) 29 (40.3 %) 0.014
Plasma creatinine (μmol/L) 113.5 +/−115.2 113.4+/−127.6 114.0 +/−101.2 NS
Renal dialysis 3 (2 %) 2 (2.6 %) 1 (1.4 %) NS
COPD 24 (16 %) 8 (10.3 %) 16 (22.2 %) 0.046
Peripheral vascular disease 25 (16.6 %) 11 (14.1 %) 14 (19.4 %) NS
Cerebrovascular disease 20 (13.3 %) 12 (15.4 %) 8 (11.1 %) NS
Euroscore 21.67 +/− 11.3 20.5 +/− 10.4 22.9 +/− 12.1 NS
STS 9.65 +/− 5.95 8.8 +/− 4.5 10.3 +/− 7.0 NS
Acute pulmonary edema 21 (14 %) 6 (7.7 %) 15 (20.8 %) 0.020
Heart failure 39 (26 %) 15 (19.2 %) 24 (33.3 %) 0.049
Syncope 6 (4 %) 3 (3.8 %) 3 (41.7 %) NS
Angor pectoris 11 (7.4 %) 7 (9.0 %) 4 (5.6 %) NS
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Table 2 Echocardiographic characteristics at baseline
Echocardiographic characteristics All patients (n = 150) Transfemoral approach (n = 78) Transapical approach (n = 72) p
Mean gradient (mmHg) 52.8 +/− 11.5 52.8 +/− 11.2 52.8 +/− 11.8 0.626
Maximal gradient (mmHg) 83.7 +/− 16.1 85.2 +/− 15.7 82.2 +/− 16.5 0.064
Vmax (m/s) 4.3 +/− 0.8 4.6 +/− 0.7 4.7 +/− 0.7 0.678
Aortic area (cm2) 0.6 +/− 0.2 0.6 +/− 0.1 0.6 +/− 0.2 0.778
LVEF (%) 52.8 +/− 12.5 51.3 +/− 13.1 54.5 +/− 11.7 0.140
Diastolic function E/E’ 11.4 +/− 4.2 12.0 +/− 4.7 10.9 +/− 3.5 0.115
Aortic annulus diameter (mm) 22.4 +/− 2.7 22.1 +/− 3.1 22.8 +/− 2.2 0.089
IVS (mm) 12.4+/− 3.0 12.6 +/− 2.4 12.7 +/− 2.3 0.936
Aortic regurgitation 74 (49.3 %) 36 (46.2 %) 38 (52.8 %) 0.137
Grade 1 38 (26 %) 22 (28.2 %) 17 (23.6 %) NS
Grade 2 34 (22 %) 12 (15.3 %) 21 (29.2 %) NS
Grade 3 2 (1.3 %) 2 (2.6 %) 0 (%) NS
Mitral regurgitation 63 (42 %) 27 (34.6 %) 36 (50.0 %) 0.128
Grade 1 29 (19.3 %) 12 (15.4 %) 17 (23.6 %) NS
Grade 2 31 (20.7 %) 15 (19.2 %) 16 (22.2 %) NS
Grade 3 3 (2 %) 0 (0 %) 3 (4.2 %) NS
PASP (mmHg) 46.3 +/− 12.6 47.6 +/− 13.0 44.7 +/− 12.0 0.147
TAPSE (mm) 15 +/− 3 14.6 +/− 3.2 15.8 +/− 2.8 0.013
Bicuspid aortic valve 1 (0.7 %) 0 (0 %) 1 (1.4 %) NS
IVS interventricular septum, LVEF left ventricular ejection fraction, PASP pulmonary artery systolic pressure, TAPSE tricuspid annular plane systolic excursion
Fig. 1 Presents the probability of survival in both the whole population and the population who died from cardiovascular diseases. Day 0
corresponds to the day of the TAVI procedure. We have not lost any of the patients to follow up. Survival rates reported at D1400 correspond to
the retrospective time of the last included patient
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analyzing single variables, we found the following pre-
dictive factors for cardiovascular mortality: preoperative
mitral regurgitation ≥Grade 2 (p = 0.024) and survival of
major complications (=0.001). However, a tendency to-
wards an increase in the cardiovascular mortality rate
was found in the following contexts: where coronary dis-
ease was present (p = 0.07), in females (p = 0.053), with
NYHA Class II or IV dyspnoea (p = 0.09), and with the
apical approach (p = 0.08). On multivariate analysis, only
the presence of a major complication was significantly
predictive of cardiovascular mortality (p = 0.003). De-
tailed results are presented in Table 4.
Complications
The postoperative complications of the whole popula-
tion have been classified and compared according to
route of approach, presented in Table 5.
A comparison of the rates of reported complications
in terms of approach method revealed significantly more
hemodynamic complications among the apical group (p
= 0.049). None of the patients who underwent surgery
via the femoral route presented with a postoperative
state of cardiogenic shock (p = 0.035). Seven patients
who had surgery via the apical route presented with
multiple organ failure, compared to two of those oper-
ated via the femoral route (p = 0.065).
On the other hand, we noted an insignificant difference
in the level of minor bleeding (p = 0.07) for the femoral
group. Transfusions were significantly more frequent in
the apical approach group, with 18 % for the femoral ap-
proach versus 28 % for the apical approach (p = 0.013).
Pulmonary complications were also significantly more fre-
quent in the apical approach cases (p = 0.029). As regards
infections, the rate of Scarpa’s fascia infection was signifi-
cantly higher in cases using the femoral approach (p =
0.007) and thoracotomy infections were significantly higher
for the apical approach (p = 0.048). Otherwise, a total of 18
pacemakers were fitted, 12/135 Edwards Sapien valves and
6/12 CoreValves. Finally, concerning the levels of renal in-
sufficiency, these were divided into 3 stages depending on
the severity of the case, using VARC classification (Stage 1
for an increase in creatininemia of 150 to 199 %, stage 2
for an increase of 200 % to 299 %, and stage 3 for an in-
crease of more than 300 % or anuria for more than 12 h).
Follow-up
Patients exhibited significant improvement in dyspnea at
1 month (p < 0.001), this improvement still proved stable
over time. The improvement in functional status was
spectacular and there has been a clear improvement in
the quality of life of our patients from the first month
following the implantation, with over half presenting as
NYHA Class I or II.
Echocardiographic results
The efficacy of TAVI was confirmed by this investiga-
tion, resulting in a drop in mean gradient of
hemodynamic flow from 52.8 to 11.8 mmHg (p < 0.001),
and the aortic surface increased from 0.6 to 1.6 cm2 (p <
0.001). These parameters remained stable throughout
the follow-up period. The interindividual variability of
the LVEF improved significantly over time (p = 0.001).
Fig. 2 Compares mortality according to route of approach, with the overall mortality rate for the femoral route and the apical route at 14 % and
25 % at 6 months, 18 % and 30 % at 1 year, and 22 % and 39 % at 2 years, respectively
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Postoperative LVEF was 52.4 % on average, compared to
52.8 % prior to surgery. We observed a significant im-
provement in the ejection fraction at one month, in-
creasing from 52.4 % to 54.6 % (p < 0.026), with this
improvement proving stable over time.
There was no significant change in the diastolic
function.
The systolic arterial pressure measurements signifi-
cantly decreased from 46.3 to 40.8 mmHg (p < 0.001)
and remained stable over time. Detailed results are pre-
sented in Table 6.
Discussion
The procedure success rate, defined as the correct de-
ployment of the prosthesis, was 94.6 % in our study, in
line with that of series reporting success rates with this
procedure of over 90 % at the test centers.[8, 9] As we
have detailed, we have kept the 6 patients who died in
the operating theatre within the 5.4 % failure rate.
Among the causes of implantation failure, one death was
linked to the anaesthesia, a secondary one to aortic pre-
dilation, another secondary to inserting the catheter
using the apical approach and the other causes were sec-
ondary to deployment of the prosthesis.
Otherwise, with regard to aortic leaks, it is currently
established thinking that a paraprosthetic leak ≥Grade 2
increases mortality from the 6th month following im-
plantation [5, 10]. Our study reported accurate results,
with a rate of 49.3 % for minor or moderate postopera-
tive paraprosthetic leaks (35 % at Grade 1 and 39 % at
Grade 2). By means of a comparison, we also searched
the FRANCE 2 data, revealing 64.5 % aortic failure [5].
Moreover, aortic regurgitation remains a challenging
pathology for the transapical approach [11]. Concerning
the evolution of paraprosthetic aortic insufficiency, our
study indeed found a tendency towards increasing the
percentage of aortic insufficiency at 6 months, 1 year,
then 2 years. Apart from statistical bias linked to the
smaller population over time, this may be linked to a
general cardiovascular aggravation, with a possible in-
crease in left ventricular postload. An important point is
the lack of major aortic insufficiency.
A large proportion of our study consisted of TAVI car-
ried out using the apical approach, with 77 of the pa-
tients (51.3 %) treated using the femoral route and 72
(48 %) using the apical route. The usual distribution is
more in favor of the femoral approach: 74 % of the pa-
tients in FRANCE 2 [5] and 69.5 % in PARTNER A [3]
received the implant via the femoral route, compared
with 19 % and 29.6 %, respectively, for the apical route.
This significantly higher percentage for the apical route
is due in part to the delay in marketing the Edwards 29
valve for the femoral route. Mortality at 6 months essen-
tially results from extracardiac causes and is linked to
comorbidities in elderly patients. This difference in mor-
tality rates is probably explained by the increased use of
the apical approach among our population, with a trend
of increased mortality in this cohort. It has, in fact, been
demonstrated that mortality rates are more significant in
the apical approach than in the femoral one [12–15].
Patients treated via the transapical route are typically
at higher risk. To date, there have been few studies com-
paring different devices or approaches. It should, never-
theless, be noted that all reports have indicated a
learning curve effect on the success rate, incidence rate,
and severity of the complications. Hemodynamic com-
plications are a major cause of perioperative death [16].
These represent 24 % of deaths at the one month mark
[16]. The significant difference in hemodynamic compli-
cations found in our study, greater in the femoral group
(Table 3), also explains the difference in mortality rate
between the two groups.
The rate of acute kidney injury (AKI) in our study (10 %)
were slightly lower than those reported in the litera-
ture.[17–19] Post-TAVI AKI was multifactorial, since pre-
operative renal function is a predictive factor independent
of post-procedural AKI [19]. Note that the level of plasma
creatinine in our cohort was 113.5 μmol/L +/−115.2, and of
the six patients who suffered stage 3 AKI, none of them
underwent dialysis apart from 3 patients who were receiv-
ing dialysis for a chronic condition already.
Table 3 Implanted prostheses diameters
Prosthesis diameter (mm) All prostheses implanted (n = 149) Transfemoral approach (n = 78) Transapical approach (n = 72) p
23 52 (34.9 %) 30 (38.5 %) 22 (30.6 %) 0.169
26 64 (42.9 %) 37 (47.4 %) 27 (37.5 %) 0.154
29 25 (16.8 %) 6 (7.7 %) 21 (29.2 %) <0.001
31 6 (4.0 %) 5 (6.4 %) 1 (1.4 %) 0.083
Table 4 Predictive factors of mortality (multivariate analysis)
Characteristics RR 95 % CI p
Female gender 2.45 [0.99–6.03] 0.051
Coronaropathy 1.84 [0.76–4.49] 0.177
NYHA Class 3 or 4 3.92 [0.52–29.6] 0.185
Major complications 9.13 [2.12–39.4] 0.003
Transapical approach 1.62 [0.7–3.75] 0.258
Mitral regurgitation (≥ Grade 2) 1.81 [0.8–4.22] 0.166
RR relative risk, CI confidence interval, NYHA New York Heart Association
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Table 5 Postoperative complications
Characteristics All patients (n = 150) Transfemoral approach (n = 78) Transapical approach (n = 72) p
Hemodynamic complications 10 (6.6 %) 2 (2.6 %) 8 (11.1 %) 0.049
state of cardiogenic shock 4 (2.7 %) 0 (0 %) 4 (5.6 %) 0.035
acute pulmonary edema 5 (3.4 %) 1 (1.3 %) 4 (5.6 %) NSS
multiple organ failure 9 (6 %) 2 (2.6 %) 7 (9.7 %) 0.065
coronary obstruction 1 (0.7 %) 1 (1.3 %) 0 (0 %) NSS
massive aortic insufficiency 1 (0.7 %) 0 (0 %) 1 (1.4 %) NSS
Vascular complications 20 (13.3 %) 11 (14.1 %) 9 (12.5 %) NSS
major vascular complications 7 (4.7 %) 4 (2.7 %) 3 (4.2 %) NSS
minor vascular complications 2 (1.3 %) 1 (1.3 %) 1 (1.4 %) NSS
mesenteric ischemia 1 (0.7 %) 1 (1.3 %) 0 (0 %) NSS
abdominal aortic aneurysm 1 (0.7 %) 1 (1.3 %) 0 (0 %) NSS
Tamponade 11 (7.4 %) 7 (9.0 %) 4 (5.6 %) NSS
Mechanical complications 8 (5.3 %) 2 (2.6 %) 6 (8.3 %) NSS
ventricular perforation 2 (1.3 %) 0 (0 %) 2 (2.8 %) NSS
VSD 1 (0.7 %) 1 (1.3 %) 0 (0 %) NSS
aortic root aneurysm 1 (0.7 %) 0 (0 %) 1 (1.4 %) NSS
aortic fistula/right atrium 1 (0.7 %) 1 (1.3 %) 0 (0 %) NSS
mitral lesion 1 (0.7 %) 0 (0 %) 1 (1.4 %) NSS
poor positioning of the valve 2 (1.3 %) 0 (0 %) 2 (2.8 %) NSS
surgical conversion 3 (2 %) 0 (0 %) 3 (4.2 %) NSS
Hemorrhagic complications 55 (36.7 %) 20 (25.7 %) 33 (45.8 %) NSS
major complications 10 (6.7 %) 3 (3.8 %) 7 (9.7 %) NSS
massive bleeding 1 (0.7 %) 0 (0 %) 1 (1.4 %) NSS
major bleeding 7 (4.7 %) 3 (3.8 %) 4 (5.6 %) NSS
minor bleeding 36 (24 %) 14 (18.0 %) 22 (30.6 %) 0.070
transfusion 42 (28 %) 15 (19.2 %) 27 (37.5 %) 0.013
Cerebral complications 10 (6.7 %) 4 (5.1 %) 6 (10.0 %) NSS
Ischemic CVA 9 (6 %) 4 (5.1 %) 5 (7.0 %) NSS
Hemorrhagic CVA 1 (0.7 %) 0 (0 %) 1 (1.4 %) NSS
Heart rhythm complications
paroxysmal atrial fibrillation 24 (16 %) 13 (16.7.7 %) 11 (15.3 %) NSS
pacemaker implanted 18 (12 %) 12 (15.4 %) 6 (8.3 %) NSS
sudden death 1 (0.7 %) 0 (0 %) 1 (1.4 %) NSS
Acute kidney injury (AKI) 15 (10 %) 7 % (9.0 %) 9 (12.5 %) NSS
Stage 1 2 (1.3 %) 1 (1.3 %) 1 (1.4 %) NSS
Stage 2 7 (4.7 %) 3 (3.8 %) 4 (4.2 %) NSS
Stage 3 6 (4 %) 3 (3.8 %) 3 (2 %) NSS
Pulmonary complications 14 (9.3 %) 2 (2.6 %) 12 (8 %) 0.029
pleural effusion 5 (3.3 %) 1 (1.3 %) 4 (5.6 %) NSS
hemothorax 1 (0.7 %) 0 (0 %) 1 (0.7 %) NSS
pneumothorax 3 (2 %) 0 (0 %) 3 (4.2 %) NSS
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The rate of pulmonary complications was higher in
the apical group compared with the femoral group, at
8 % vs. 1.3 % (p = 0.029). This constituted one of the
most predominant causes of morbidity and mortality in
the apical group. Nevertheless, we found no significant
difference in rate of tamponade during the postoperative
period when comparing the two approaches, namely
4.7 % in the apical group versus 2.7 % in the femoral
group.
Pre-TAVI mitral regurgitation was identified in our
study as a risk factor for mortality when Grade 2 or
higher, as other studies have also observed [20–23]. The
post-TAVI mitral regurgitation in our cohort showed a
tendency to increase over time. The evolution of post-
TAVI mitral regurgitation remains discordant, depend-
ing on the studies [3, 24, 25]. In our case, it can be ex-
plained by statistical bias linked to a reduction in
population monitored over time, general age-linked
Table 5 Postoperative complications (Continued)
Infectious complications 18 (12 %) 12 (15.4 %) 6 (8.3 %) NSS
Scarpa’s fascia infection 11 (7.4 %) 10 (12.8 %) 1 (1.4 %) 0.007
thoracotomy infection 4 (2.7 %) 0 (0 %) 4 (5.6 %) 0.048
endocarditis 3 (2 %) 2 (2.6 %) 1 (1.4 %) NSS
CVA cerebrovascular accident, VSA ventricular septal defect, AKI Acute kidney injury
Table 6 Echocardiographic postoperative results
Echocardiographic characteristics Preoperative Postoperative One month Six months One year Two years
Population (n) n = 150 n = 144 n = 125 n = 101 n = 52 n = 25
Mean gradient (mmHg) 52.8 +/−11.5 11.8+/−4.9 11+/−4.6 11.5+/−5.2 11.9+/−4.4 11.2+/−3.8
p < 0.001 p < 0.001
Maximal gradient (mmHg) 83.7 +/−16.1 21.5+/−8.1 22.1+/−18.8 21.4+/−7.7 20.5+/−5.6 19.6+/−4.3
p < 0.001 p < 0.001
Vmax (m/s) 4.3 +/−0.8 2.1+/−0.4 1.7+/−0.5 1.7+/−0.6 1.6+/−0.5 1.7+/−0.5
p < 0.001 p < 0.001
Aortic area (cm2) 0.6 +/−0.2 1.6+/−0.4 1.2+/−0.4 1.2+/−0.3 1.2+/−0.4 1.2+/−0.4
p < 0.001 p < 0.001
LVEF (%) 52.8+/−12.5 52.4+/−12.1 54.6+/−10.4 55+/−10.7 54.4+/−10.9 52.8+/−12.5
p = 0.002 p = 0.026 p = 0.056
Diastolic function E/E’ 11.4+/−4.2 11.4+/−3.8 11.5+/−3.4 11.7+/−3.8 11.5+/−3.4 11.7+/−3.9
NS
PAPS (mmHg) 46.3+/− 12.6 40.8+/−12 41.7+/−10.7 41.5+/−10.5 40.5+/−11.2 38.8+/−6.4
p = 0.006 p < 0.001 p = 0.078 p = 0.045
TAPSE (mm) 15.2+/−3 13.8+/−3.2 15.4+/−3 15.1+/−2.9 14.8+/−3.4 14.2+/−3.2
NS
Central aortic regurgitation / 4 (2.8 %) 3 (2.4 %) 2 (2.0 %) 1 (1.9 %) 0 (0 %)
NS
Paraprosthetic regurgitation / 74 (51.4 %) 38 (30.4 %) 14 (13.8 %) 10 (19.2 %) 8 (32.0 %)
p < 0.001
Grade 1 / 35 (24.3 %) 24 (19.2 %) 6 (59.4 %) 6 (11.5 %) 6 (24.0 %)
Grade 2 / 39 (27.1 %) 13 (10.6 %) 8 (7.9 %) 4 (7.6 %) 2 (8 %)
Mitral regurgitation 63 (42 %) 83 (57.6 %) 88 (70.6 %) 72 (71.2 %) 37 (71.1 %) 19 (76.0 %)
Grade 1 29 (19.3 %) 12 (8.3 %) 49 (32.2 %) 33 (32.6 %) 15 (19.2 %) 8 (32.0 %)
Grade 2 31 (20.7 %) 71 (49.3 %) 39 (31.2 %) 39 (38.6 %) 22 (42.3 %) 11 (44.0 %)
Grade 3 3 (2 %) 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %) 0 (0 %)
LVEF left ventricular ejection fraction, PASP pulmonary artery systolic pressure, TAPSE tricuspid annular plane systolic excursion
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cardiovascular deterioration, the tendency towards an in-
crease in aortic insufficiency in our cohort or the high
proportion of ischemic patients (46.6 %).On the other
hand, the mechanism underlying the mitral regurgitation
is an important factor [26]. The functional nature of the
leak and presence of left ventricular failure are predictive
factors for the reduction in mitral valve disease. Con-
versely, its organic nature, the dilatation of the left
atrium, and the existence of pulmonary artery hyperten-
sion all suggest a lack of improvement [27].
Finally, the rate of major vascular complications was
relatively low in our study, reported at 4.7 %. Taking into
account minor vascular complications, the overall rate
was 6 %. This could be as a result of the high percentage
of apical approaches used. Vascular complications were
found to remain a significant source of morbidity in the
transfemoral route, with an incidence of 9.7 % [5]. Re-
duction in major vascular complications from 8 to 1 %
has been demonstrated with the benefit of a more pre-
cise selection of patients, a completely percutaneous vas-
cular approach, and advances in surgical techniques
[28]. This demonstrated that the number of vascular
complications and survival rate increases in parallel with
increased experience of each center and over time [29].
Conclusions
TAVI has been confirmed as a credible alternative to
surgical valve replacement and has become the first
therapeutic choice for non-operable patients and a valid
alternative for high-risk patients. The mid-term results
of the first 150 TAVI procedures, conducted from 2009
to 2013 in our center, demonstrated mortality rates of
4 %, 11.3 %, 22.7 % and 26 % at the immediate peri-
operative point, 31 days, 1 year, and 2 years, respectively.
The interindividual variability of LVEF improved signifi-
cantly over time (p = 0.001). Our study revealed a trend
towards increased probability of survival in the femoral
group compared to the apical group. On comparing the
rates of complications in terms of approach method, we
observed that the patients treated through the transapi-
cal route, who are usually at higher risk, exhibited sig-
nificantly more hemodynamic complications (p = 0.049)
and more pulmonary complications (p = 0.029). These
results underline the importance of a multidisciplinary
decision concerning the choice of approach type.
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